Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue.

BACKGROUND

Hepatitis B virus (HBV) nucleos(t)ide analog (NA) therapy reduces liver disease but requires prolonged therapy to achieve hepatitis B surface antigen (HBsAg) loss. There is limited North American real-world data using non-invasive tools for fibrosis assessment and few have compared 1 generation NA or lamivudine (LAM) to tenofovir disoproxil fumarate (TDF).

AIM

To assess impact of NA on virological response and fibrosis regression using liver stiffness measurement (LSM) (, FibroScan).

METHODS

Retrospective, observational cohort study from the Canadian HBV Network. Data collected included demographics, NA, HBV DNA, alanine aminotransferase (ALT), and LSM. Patients were HBV monoinfected patients, treatment naïve, and received 1 NA with minimum 1 year follow-up.

RESULTS

In 465 (median 49 years, 37% female, 35% hepatitis B e antigen at baseline, 84% Asian, 6% White, and 9% Black). Percentage of 64 ( = 299) received TDF and 166 were LAM-treated with similar median duration of 3.9 and 3.7 years, respectively. The mean baseline LSM was 11.2 kPa (TDF) 8.3 kPa (LAM) ( = 0.003). At 5-year follow-up, the mean LSM was 7.0 kPa in TDF 6.7 kPa in LAM ( = 0.83). There was a significant difference in fibrosis regression between groups (, mean -4.2 kPa change in TDF and -1.6 kPa in LAM, < 0.05). The last available data on treatment showed that all had normal ALT, but more TDF patients were virologically suppressed (< 10 IU/mL) ( = 170/190, 89%) LAM-treated ( = 35/58, 60%) ( 0.05). None cleared HBsAg.

CONCLUSION

In this real-world North American study, approximately 5 years of NA achieves liver fibrosis regression rarely leads to HBsAg loss.